Latest "Seattle Biomedical Research Institute" News Stories

06:11 EDT 24th March 2018 | BioPortfolio

Here are the most relevant search results for "Seattle Biomedical Research Institute" found in our extensive news archives from over 250 global news sources.

More Information about Seattle Biomedical Research Institute on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Seattle Biomedical Research Institute for you to read. Along with our medical data and news we also list Seattle Biomedical Research Institute Clinical Trials, which are updated daily. BioPortfolio also has a large database of Seattle Biomedical Research Institute Companies for you to search.

Showing "Seattle Biomedical Research Institute" News Articles 1–25 of 29,000+

Extremely Relevant

Promising new drug for Hep B tested at Texas Biomedical Research Institute

(Texas Biomedical Research Institute) Research at the Southwest National Primate Research Center (SNPRC) on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection.

Texas Biomedical Research Institute tests promising new treatment for HBV infection

Research at the Southwest National Primate Research Center on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection.

Texas Biomedical Research Institute Tests Promising New Drug for Hepatitis B

Research at the Southwest National Primate Research Center (SNPRC) on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection. Testing at SNPRC provided proof this novel therapeutic approach and drug delivery mechanism would be safe and effective, as

Search for novel biomarkers indicating early cardiovascular disease risk wins funding

(Texas Biomedical Research Institute) Texas Biomedical Research Institute scientists have been granted funding from the National Institutes of Health to pursue a promising study on the ultimate causes of heart disease and metabolic disorders.


New model for Zika developed to aid in testing vaccines and treatments

(Texas Biomedical Research Institute) An alternative animal model that mimics key features of the Zika virus infection, including its lingering presence in bodily fluids, has been developed at Texas Biomedical Research Institute in San Antonio.

Texas researchers take on mysterious children's illness

(Texas Biomedical Research Institute) Texas Biomedical Research Institute and The Children's Hospital of San Antonio have joined forces to cure a mysterious condition called Kawasaki disease. The illness which affects young children is named after the Japanese doctor who first described it more than 50 years ago.

IDIBELL researchers successfully test a new combination therapy in sarcomas

(IDIBELL-Bellvitge Biomedical Research Institute) Researchers of the Sarcoma group of the Oncobell program -- Bellvitge Biomedical Research Institute (IDIBELL) have successfully tested a new combined therapy for the treatment of this rare, aggressive tumor type, which affects children and adults.

Promising treatment for Ebola to be tested at Texas Biomed

(Texas Biomedical Research Institute) During the West African Ebola outbreak that began in 2013, an experimental biopharmaceutical drug called ZMappTM was a glimmer of hope in the midst of a health crisis. Now, scientists at Texas Biomedical Research Institute in San Antonio have been awarded a $2 million dollar contract by the makers of ZMapp, Mapp Biopharmaceutical, Inc., to further test this pr...

New Seattle precision medicine institute will catalog 60K breast cancer gene mutations

Body:  A $50 million donation by Jeffrey and Susan Brotman and Pam and Dan Baty will help create the Brotman Baty Institute for Precision Medicine, according to a recent University of Washington news release. The institute will combine the expertise of UW Medicine, Fred Hutchinson Cancer Research Center in Seattle and Seattle Children's Hospital.  According to the r

Large-scale approach reveals imperfect actor in plant biotechnology

(Whitehead Institute for Biomedical Research) A research team led by Whitehead Institute has unraveled the molecular activities of a key protein that can enable plants to withstand a common herbicide. Their findings reveal how the protein can sometimes act imprecisely, and how it can be successfully re-engineered to be more precise.

Non-car commuting options winning over downtown Seattle workers in droves

So, what’s it like for a city’s downtown workers to forego the car and utilize other means in terms of satisfying or fulfilling duties? Just ask Seattle, Washington, the Pacific Northwest-located city. Commute Seattle in a 2014 “Downtown Seattle Commuter Trends” press release reported, “[m]ore people are commuting to Downtown Seattle than ever, but the […]

TGen tests ultrasound as way to enhance cancer drug delivery

(The Translational Genomics Research Institute) A Norwegian biotech company called Phoenix Solutions AS is working with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility, to test the use of these pulsed sound waves to direct and focus cancer drug therapies.

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

(Seattle Children's) Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

NIH experts call for transformative research approach to end tuberculosis

(NIH/National Institute of Allergy and Infectious Diseases) A more intensive biomedical research approach is necessary to control and ultimately eliminate tuberculosis (TB), according to a perspective published in The American Journal of Tropical Medicine and Hygiene. In the article, authors Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, and Robert W...

How Alzheimer’s disease spreads throughout the brain – new study – The Conversation UK

The Conversation UKHow Alzheimer's disease spreads throughout the brain – new studyThe Conversation UKThomas E Cope receives funding from the Patrick Berthoud Charitable Trust and the Association of British Neurologists. The NIMROD study was funded by the National Institute for Health Research, Cambridge Biomedical Research Centre and Biomedical ...Advances in PET settle debate over spread of ke...

Zacks: Analysts Expect Seattle Genetics, Inc. (SGEN) Will Post Earnings of -$0.44 Per Share

Equities research analysts expect Seattle Genetics, Inc. to report earnings per share for the current quarter, according to Zacks Investment Research . Six analysts have made estimates for Seattle Genetics' earnings.

Three Duke biomedical engineers join National Academy of Inventors

(Duke University) The National Academy of Inventors (NAI) has elected three faculty members from Duke University's department of biomedical engineering to its 2017 class of Fellows: Joseph Izatt, the Michael J. Fitzpatrick Professor of Engineering; Nimmi Ramanujam, the Robert W. Carr, Jr. Professor of Biomedical Engineering and the director of the Global Women's Health Technologies Center; and Tua...

Seattle Genetics Acquires Cascadian Therapeutics, Continuing a Strong ...

On January 31, two Seattle biotech companies, Seattle Genetics and Cascadian Therapeutics, announced a merger agreement under which Seattle Genetics will acquire Cascadian Therapeutics for $614 million. [1] The announcement catapulted Cascadian Therapeutics shares to a 16-month high, and a 69% increase over the previous day's closing price.

Seattle Genetics to Acquire Cascadian Therapeutics for $614 Million, Adding Late-Stage Breast Cancer Program

att BOTHELL, Wash. & SEATTLE–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) and Cascadian Therapeutics, Inc. (Nasdaq:CASC) today announced the signing of a definitive merger agreement under which Seattle Genetics has agreed to acquire Cascadian Therapeutics. Under the terms of the agreement, Seattle Genetics will pay $10.00 per share in cash, or approximately $614 million. T...

BU researchers create tool to measure, control protein aggregation

(Boston University College of Engineering) In the cover article in the current issue of Cell, BU Biomedical Engineer Ahmad S. Khalil along with colleagues from MIT and the Whitehead Institute for Biomedical Research, among others, describe the synthetic genetic tool they built to quantitatively sense, measure and manipulate protein aggregation in live cells. This may open the door to greater under...

Seattle Museum Month Means Big Savings for Visitors in February

A wide array of institutions, attractions, and exhibits are part of this offer including the Seattle Art Museum, Tacoma Art Museum, Seattle Children's Museum, Museum Read more...

Study reveals key molecular link in major cell growth pathway

(Whitehead Institute for Biomedical Research) A team of scientists led by Whitehead Institute has uncovered a surprising molecular link that connects how cells regulate growth with how they sense and make available the nutrients required for growth. The researchers' findings also implicate a new protein, SLC38A9, as a potential drug target in pancreatic cancer.

Opinion: The NIH is in danger of losing its edge in creating biomedical innovations

Biomedical research in the U.S is flagging. Here's how we would fix it.

PharmaMar lizensiert vollsynthetisch aus Meeressubstanzen gewonnene Payloads für Wirkstoff-Konjugate an Seattle Genetics

Madrid (ots/PRNewswire) - PharmaMar (MCE: PHM) hat heute die Unterzeichnung einer exklusiven Lizenzvereinbarung mit Seattle Genetics Inc. (SGEN: NASDAQ GS) bekanntgegeben, nach der Seattle Genetics...

New interdisciplinary research program in biomedical innovation law

(University of Copenhagen, Faculty of Law) The Novo Nordisk Foundation has awarded a grant of DKK 35 million to Timo Minssen, Professor, Faculty of Law, University of Copenhagen for establishing a Collaborative Research Programme in Biomedical Innova-tion Law (CeBIL).The aim of CeBIL is to analyse the most important legal obstacles to pharmaceutical innovation and thereby contribute to translating...

Quick Search


News Quicklinks